Research Summary

Yiwey Shieh, MD is an Assistant Professor in the Department of Medicine at the University of California, San Francisco (UCSF). Dr. Shieh is a general internist and clinical epidemiologist interested in improving the delivery of breast cancer screening and prevention through the use of risk stratification tools. His current work uses clinical risk factors, breast density, and genetic variants to refine individualized risk assessment, especially as it pertains to disease biology. As a clinician-investigator, he is particularly interested in how such tools can be used to improve clinical decision-making.

Research Funding

  • July 1, 2019 - June 30, 2024 - Prediction of interval breast cancer risk using genetic variants, Principal Investigator. Sponsor: NIH, Sponsor Award ID: K08CA237829
  • June 1, 2018 - June 30, 2019 - UCSF CTSI KL2 Career Development Award, KL2 Scholar. Sponsor: NIH/NCATS, Sponsor Award ID: 1KL2TR001870
  • July 1, 2019 - June 30, 2024 - Prediction of interval breast cancer risk using genetic variants, Principal Investigator. Sponsor: NIH, Sponsor Award ID: K08CA237829
  • June 1, 2018 - June 30, 2019 - UCSF CTSI KL2 Career Development Award, KL2 Scholar. Sponsor: NIH/NCATS, Sponsor Award ID: 1KL2TR001870

Education

Harvard University, AB, 06/2006, Biology, Cum Laude
University of California, San Francisco, MD, 06/2012, Medicine
Hospital of the University of Pennsylvania, Resident, 06/2015, Internal Medicine-Primary Care
University of California, San Francisco, Primary Care Research Fellow, 06/2017
UCSF Department of Epidemiology and Biostatistics, Master of Advanced Study 06/2017 Clinical Research

Honors & Awards

  • 2010
    Featured Poster, Cancer Prevention and Epidemiology Discussion Session, American Society of Clinical Oncology Annual Meeting
  • 2011
    Finalist, Dean's Prize in Research, UCSF School of Medicine
  • 2012
    Nominee, Essential Core Teaching Award, UCSF School of Medicine
  • 2016
    Featured Poster, Women's Health Poster Walking Tour, Society of General Internal Medicine Annual Meeting
  • 2017
    Best Poster, Epidemiology and Population Science, UCSF Breast Oncology Program Retreat
  • 2017
    Finalist, Mack Lipkin Sr. Associate Member Scientific Presentation Award, Society of General Internal Medicine Annual Meeting
  • 2018
    Winner, Milton W. Hamolsky Junior Faculty Scientific Presentation Award, Society of General Internal Medicine Annual Meeting
  • 2019
    Nominee, Robert H. Crede Award for Clinical Care, UCSF Division of General Internal Medicine
  • 2019
    Nominee, Robert H. Crede Award for Research, UCSF Division of General Internal Medicine
  • 2019
    Recipient of K08 Career Development Award, National Cancer Institute

Selected Publications

  1. Dreher N, Matthys M, Hadeler E, Shieh Y, Acerbi I, McAuley FM, Melisko M, Eklund M, Tice JA, Esserman LJ, Veer LJV. A case-case analysis of women with breast cancer: predictors of interval vs screen-detected cancer. Breast Cancer Res Treat. 2021 Nov 29.  View on PubMed
  2. Esserman L, Eklund M, Veer LV, Shieh Y, Tice J, Ziv E, Blanco A, Kaplan C, Hiatt R, Fiscalini AS, Yau C, Scheuner M, Naeim A, Wenger N, Lee V, Heditsian D, Brain S, Parker BA, LaCroix AZ, Madlensky L, Hogarth M, Borowsky A, Anton-Culver H, Kaster A, Olopade OI, Sheth D, Garcia A, Lancaster R, Plaza M. The WISDOM study: a new approach to screening can and should be tested. Breast Cancer Res Treat. 2021 Oct; 189(3):593-598.  View on PubMed
  3. Huilgol YS, Keane H, Shieh Y, Hiatt RA, Tice JA, Madlensky L, Sabacan L, Fiscalini AS, Ziv E, Acerbi I, Che M, Anton-Culver H, Borowsky AD, Hunt S, Naeim A, Parker BA, van 't Veer LJ, Athena Breast Health Network Investigators and Advocate Partners, Esserman LJ. Elevated risk thresholds predict endocrine risk-reducing medication use in the Athena screening registry. NPJ Breast Cancer. 2021 Aug 03; 7(1):102.  View on PubMed
  4. Keane H, Huilgol YS, Shieh Y, Tice JA, Belkora J, Sepucha K, Shibley WP, Wang T, Che M, Goodman D, Ozanne E, Fiscalini AS, Esserman LJ. Development and pilot of an online, personalized risk assessment tool for a breast cancer precision medicine trial. NPJ Breast Cancer. 2021 Jun 17; 7(1):78.  View on PubMed
  5. Shieh Y, Tice JA. Medications for Primary Prevention of Breast Cancer. JAMA. 2020 07 21; 324(3):291-292.  View on PubMed
  6. Shieh Y, Fejerman L, Lott PC, Marker K, Sawyer SD, Hu D, Huntsman S, Torres J, Echeverry M, Bohórquez ME, Martínez-Chéquer JC, Polanco-Echeverry G, Estrada-Flórez AP, COLUMBUS Consortium , Haiman CA, John EM, Kushi LH, Torres-Mejía G, Vidaurre T, Weitzel JN, Zambrano SC, Carvajal-Carmona LG, Ziv E, Neuhausen SL. A Polygenic Risk Score for Breast Cancer in US Latinas and Latin American Women. J Natl Cancer Inst. 2020 06 01; 112(6):590-598.  View on PubMed
  7. Shieh Y, Ziv E, Kerlikowske K. Interval breast cancers - insights into a complex phenotype. Nat Rev Clin Oncol. 2020 03; 17(3):138-139.  View on PubMed
  8. Shieh Y, Scott CG, Jensen MR, Norman AD, Bertrand KA, Pankratz VS, Brandt KR, Visscher DW, Shepherd JA, Tamimi RM, Vachon CM, Kerlikowske K. Body mass index, mammographic density, and breast cancer risk by estrogen receptor subtype. Breast Cancer Res. 2019 04 03; 21(1):48.  View on PubMed
  9. Antoniou A, Anton-Culver H, Borowsky A, Broeders M, Brooks J, Chiarelli A, Chiquette J, Cuzick J, Delaloge S, Devilee P, Dorval M, Easton D, Eisen A, Eklund M, Eloy L, Esserman L, Garcia-Closas M, Goldgar D, Hall P, Knoppers BM, Kraft P, La Croix A, Madalensky L, Mavaddat N, Mittman N, Nabi H, Olopade O, Pashayan N, Schmidt M, Shieh Y, Simard J, Stover-Fiscallini A, Tice JA, Van't Veer L, Wenger N, Wolfson M, Yau C, Ziv E. A response to "Personalised medicine and population health: breast and ovarian cancer". Hum Genet. 2019 Mar; 138(3):287-289.  View on PubMed
  10. Nickolas Dreher, Irene Acerbi, Edward Kenji Hadeler, Yiwey Shieh, Michelle E. Melisko, Athena Investigators and Advocates, Laura Esserman, Laura van 't Veer. A breast cancer risk model as a predictor of interval cancer rate and tumor characteristics. Journal of Clinical Oncology. 2018 May 20; 36(15_suppl):1506-1506.  View on PubMed
  11. Esserman LJ, WISDOM Study and Athena Investigators . The WISDOM Study: breaking the deadlock in the breast cancer screening debate. NPJ Breast Cancer. 2017; 3:34.  View on PubMed
  12. Shieh Y, Hu D, Ma L, Huntsman S, Gard CC, Leung JWT, Tice JA, Ziv E, Kerlikowske K, Cummings SR. Joint relative risks for estrogen receptor-positive breast cancer from a clinical model, polygenic risk score, and sex hormones. Breast Cancer Res Treat. 2017 Nov; 166(2):603-612.  View on PubMed
  13. Shieh Y, Bohnenkamp M. Low-Dose CT Scan for Lung Cancer Screening: Clinical and Coding Considerations. Chest. 2017 07; 152(1):204-209.  View on PubMed
  14. Shieh Y, Eklund M, Madlensky L, Sawyer SD, Thompson CK, Stover Fiscalini A, Ziv E, Van't Veer LJ, Esserman LJ, Tice JA, Athena Breast Health Network Investigators . Breast Cancer Screening in the Precision Medicine Era: Risk-Based Screening in a Population-Based Trial. J Natl Cancer Inst. 2017 01; 109(5).  View on PubMed
  15. Shieh Y, Hu D, Ma L, Huntsman S, Gard CC, Leung JW, Tice JA, Vachon CM, Cummings SR, Kerlikowske K, Ziv E. Breast cancer risk prediction using a clinical risk model and polygenic risk score. Breast Cancer Res Treat. 2016 Oct; 159(3):513-25.  View on PubMed
  16. Shieh Y, Eklund M, Sawaya GF, Black WC, Kramer BS, Esserman LJ. Population-based screening for cancer: hope and hype. Nat Rev Clin Oncol. 2016 09; 13(9):550-65.  View on PubMed
  17. Shieh Y, Eklund M, Esserman L. Detection of ductal carcinoma in situ and subsequent interval cancers. BMJ. 2016 Feb 01; 352:i551.  View on PubMed
  18. Esserman LJ, Shieh Y, Rutgers EJ, Knauer M, Retèl VP, Mook S, Glas AM, Moore DH, Linn S, van Leeuwen FE, van 't Veer LJ. Impact of mammographic screening on the detection of good and poor prognosis breast cancers. Breast Cancer Res Treat. 2011 Dec; 130(3):725-34.  View on PubMed
  19. Ozanne EM, Shieh Y, Barnes J, Bouzan C, Hwang ES, Esserman LJ. Characterizing the impact of 25 years of DCIS treatment. Breast Cancer Res Treat. 2011 Aug; 129(1):165-73.  View on PubMed
  20. Y. Shieh, L. Esserman, E. J. Rutgers, M. Knauer, V. Retel, S. Mook, A. Glas, S. C. Linn, F. E. van Leeuwen, L. van't Veer. Effect of screening on the detection of good and poor prognosis breast cancers. Journal of Clinical Oncology. 2010 May 20; 28(15_suppl):1520-1520.  View on PubMed

Go to UCSF Profiles, powered by CTSI